Featured Story | By Ben Adams As the months tick down before the November election, President Donald Trump is seemingly under increasing pressure to find vaccines and treatments for COVID-19. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Bristol Myers Squibb has taken out a lease on a 360,000-square-foot site in Massachusetts. Securing the facility, which is walking distance from Kendall Square, will enable Bristol Myers to combine its two existing Cambridge R&D sites into a single location. read more By Nick Paul Taylor Turning Point Therapeutics has posted early phase 2 data on ALK inhibitor repotrectinib that suggest it may pose a threat to Roche’s Rozlytrek. Buoyed by the data, Turning Point is tweaking the trial with a view to pulling forward a filing for FDA approval. read more By BioIVT While the response to COVID-19 and other disease indications drives science forward, regulatory guidelines that ensure the safe and ethical treatment of patients continues to be critically important. read more By Amirah Al Idrus Inhibrx may have called off its first IPO attempt last fall, but its second go has proved much more fruitful. The antibody specialist raised $119 million in its Wall Street debut, far eclipsing the $75 million it originally sought last year. The funds will support phase 1 studies for multiple antibody candidates. read more By Amirah Al Idrus Alzheon has been trying to go public for years, calling off its IPO in April 2018 and aborting its second attempt in January last year. Now, public markets be damned, the company is moving forward with a phase 3 study of its lead Alzheimer’s program thanks to a $47 million grant from the National Institutes of Health. read more By Conor Hale Qiagen launched new tools to capture and track emerging mutations in the novel coronavirus, which can lead to new strains that may change how the world responds to the COVID-19 pandemic. read more By Angus Liu Scientists at the Salk Institute created functional, three-dimensional human islet-like organoids that restored glucose control in mice without triggering immune rejection. The trick was to induce the expression of the PD-L1 immune checkpoint protein. read more By Eric Sagonowsky Officials in Europe have engaged some of the world's largest biopharma companies in COVID-19 vaccine supply talks, but now Germany’s CureVac is moving into advanced supply negotiations with the union. The deal, which is contingent on the vaccine succeeding in testing, would potentially allow for the purchase of 405 million doses. read more Enrollment Showcase | Presented by: Biotility Taught by experienced professionals, Biotility’s online short courses provide the knowledge and practical skills valued by the bioscience industry. Enhance your career through coursework in one of our certificate pathways, including Document Management, Operations Management, and Quality Management. Learn more. |
| |
|---|
|
Resources Sponsored by: LexisNexis Risk Solutions Traditionally, pharma companies use a combination of prescription data & internal sales reports to look for potential buyers. Such practice provides only a LIMITED VIEW without competitor information. Sponsored by: Oracle Health Sciences Patient-facing digital technologies are playing an important role in clinical trials for new drugs and medical devices, to the point where conducting virtual trials is becoming mainstream. But terms like remote trials, direct-to-patient trials, hybrid trials, decentralized trials, and more all add to the confusion of what makes a trial "virtual." Sponsored by: Oracle Health Sciences The research conducted here is to help understand and solve the top challenges in clinical operations, to remove barriers that are slowing down our ability to bring new drugs to market as quickly as possible to patients waiting in need. Sponsored by: Thermo Fisher Scientific How to select the right dosage form for your Phase I clinical supply. Sponsored by: Thermo Fisher Scientific Quality by Design (QbD) reduces risk within drug development, while bringing therapies to market quicker. Sponsored by: Evotec Two informative webcasts will present practical and methodological approaches to preclinical drug abuse liability assessment Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Acorn AI by Medidata, a Dassault Systèmes company Case Study: Oncology-focused pharmaceutical company strengthens product launch by identifying hundreds of high-value physicians with Acorn AI. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Cardinal Health 3PL Services Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: PRA Health Sciences Drug developers and stakeholders must find ways to collaborate, rather than compete, as the RACE Act prompts the need for more pediatric research. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
